BHYLOR
Live / Allowed — First extension granted (statement of use) (as of 25 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 31 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99112415
- Mark type
- Word mark
- Filed
- 31 Mar 2025
- Published for opposition
- 06 Jan 2026
- Attorney of record
- Holly Pekowsky
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of hypertension, sleep apnea, chronic kidney disease, heart failure, primary aldosteronism, myocardial infarction, coronary artery disease, blood vessel wall thickening, renal fibrosis, nephropathy, and vascular dementia
Owner
- Mineralys Therapeutics, Inc., Radnor, PA, US
- Mineralys Therapeutics, Inc., Radnor, PA, US
Prosecution history
- 26 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Mar 2026 — SOU EXTENSION 1 GRANTED
- 25 Mar 2026 — SOU EXTENSION 1 FILED
- 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 06 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 06 Jan 2026 — PUBLISHED FOR OPPOSITION
- 31 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 Dec 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 24 Nov 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 24 Nov 2025 — FINAL REFUSAL E-MAILED
- 24 Nov 2025 — FINAL REFUSAL WRITTEN